custom image

Joint meeting with Fatty Liver Disease and Multi-System Complications

Hepatobiliary Cancers: Pathobiology and Translational Advances

March 22-24, 2021 | 10:00AM EDT | 2:00PM UTC | 3:00PM CET*
*Program is in development and subject to change


The live portion of this conference has concluded and all presentations are now available for purchase on demand. Registrants to the live event may access this content anytime for up to 9 months following the event.

 Free Access to On Demand Content to Scientists from Low-and Middle-Income Countries

Keystone Symposia welcomes the global scientific community and aims to connect researchers within and across disciplines to accelerate the advancement of biomedical and life sciences. This form may be used for scientists from low- and middle-income countries of all career stages to determine eligibility and request free access to scientific content presented during recent eSymposia events. If eligible, you will be sent an access code for the On Demand content of the eSymposia event(s) of interest.

Apply Here

Hepatobiliary cancers, including hepatocellular carcinomas (HCC) and intrahepatic cholangiocarcinomas (iCCA), represent a major global health burden that continues to challenge biological researchers and clinicians alike. Hepatobiliary cancers are the second or third leading cause of cancer mortality worldwide, with over 840,000 new cases diagnosed in 2018. This Keystone Symposia meeting will be the first of its kind to focus specifically on this challenging disease. The meeting aims to integrate emerging basic and translational research with the clinical perspective, in order to advance our understanding of the pathobiology behind both HCC and iCCA, with the ultimate goal of guiding novel treatment and prevention strategies targeting these underlying mechanisms. 

The program will explore current challenges in the field, including (1) shifting etiological trends, focusing on mechanisms linked to cell injury, inflammation, and fibrogenesis; (2) roles of the microbiome and tumor microenvironment in affecting disease progression, therapeutic resistance, and immunosurveillance; (3) challenges of inter-and intra-tumoral heterogeneity; (4) identification of novel and more effective biomarker signatures for monitoring prognosis and treatments; (5) advances in “omics” for personalizing therapies; and (6) current and emerging trends in molecular and immune targeting. Moreover, this unique meeting is paired with a joint meeting on fatty liver disease, which is a perfect fit in lieu of the fact that non-alcoholic steatohepatitis is an important risk factor for hepatobiliary cancer. These joint meetings will foster new and productive research collaborations towards both basic and translational advances, as well as offer valuable training opportunities for basic researchers and clinician scientists.

Apply Here for Free On Demand Access


Regular Registration Rate: $275 USD
Student Registration Rate: $150 USD


Abstract Submission:
‣ For Short Talk Consideration: Passed
‣ For Poster Booth: Passed
ePoster / SciTalk Submission: Passed
Financial Aid Application: Passed

*Abstract submission is required in order to submit an ePoster and/or Scitalk


Program Details

Keynote Speakers

custom image

Helen H. Hobbs
University of Texas Southwestern Medical Center

custom image

Hashem B. El-Serag
Baylor College of Medicine

Speaking at this eSymposia

Silvia Affo

Columbia University, USA

Jesper Bøje Andersen

University of Copenhagen, Denmark

Renumathy Dhanasekaran

Stanford University, USA

Hashem B. El-Serag

Baylor College of Medicine, USA

Gregory J. Gores

Mayo Clinic, USA

Tim F. Greten

NCI, National Institutes of Health, USA

Daniel A. Heller

Memorial Sloan Kettering Cancer Center, USA

Helen H. Hobbs

University of Texas Southwestern Medical Center, USA

Jay D. Horton

University of Texas Southwestern Medical Center, USA

Yujin Hoshida

UT Southwestern Medical Center, USA

R. Kate Kelley

University of California, San Francisco, USA

Josep Llovet

Icahn School of Medicine at Mount Sinai, USA

Amaia Lujambio

Icahn School of Medicine at Mount Sinai, USA

Lopa Mishra

George Washington University, USA

Irene Oi Lin Ng

University of Hong Kong, Hong Kong

Maria Rescigno

Humanitas University, Italy

Bruno Sangro

Clinica Universidad de Navarra, Spain

Robert F. Schwabe

Columbia University, USA

Alphonse E. Sirica

Virginia Commonwealth University, USA

Bin Tean Teh

Duke-NUS Medical School, Singapore

Augusto Villanueva Rodriguez

Icahn School of Medicine at Mount Sinai, USA

Xin Wei Wang

NCI, National Institutes of Health, USA

Jessica Zucman-Rossi

University Paris Descartes-HEGP, France


This new virtual meeting format came out of difficult circumstances, but your commitment to scientific progress is what inspired us to launch Keystone eSymposia. In these virtual meetings, we are capturing the same innovative essence of our in-person meetings that you've all created as a scientific community. Here, Debbie Johnson, our CEO, explains how we're going to do that.

The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.

Donate to Keystone Symposia

custom image